Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues - Additional Information (Detail)

Revenues - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended	12 Months Ended			1 Months Ended
Revenues - Additional Information (Detail) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Aug. 31, 2009	Dec. 31, 2014	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2010	May 31, 2011	Feb. 28, 2013
Deferred Revenue Arrangement [Line Items]
Revenues from product sales	$ 0us-gaap_SalesRevenueGoodsNet
Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	0	300,000
Allergan Inc [Member] \| Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	0
Allergan Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments	13,000,000
Allergan Inc [Member] \| Collaborative Arrangement [Member] \| Upfront Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, license revenue			10,000,000
Sanofi [Member] \| Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments				300,000
Collaboration agreement, revenue recognized	0			500,000
Description of factors in determining milestones substantive	Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.
Collaborative arrangement, consideration							8,100,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Expired Option Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, revenue recognized					700,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Options Exercised [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, revenue recognized						350,000
Collaborative arrangement, consideration									270,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Options, Exercised Price [Member]
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement, consideration									1,100,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Licenses [Member]
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement, consideration							3,500,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Options to Acquire Additional Licenses [Member]
Deferred Revenue Arrangement [Line Items]
Collaborative arrangement, consideration							1,400,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Research Services [Member]
Deferred Revenue Arrangement [Line Items]
Research collaboration agreement, estimated period						2 years
Collaborative arrangement, consideration							3,200,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Research Services [Member] \| Extension Term [Member]
Deferred Revenue Arrangement [Line Items]
Research collaboration agreement, estimated period						40 months
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments							49,600,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Research Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments							1,800,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Development Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments							28,500,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments							19,300,000
Sanofi [Member] \| Collaborative Arrangement [Member] \| Upfront Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, license revenue							4,900,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Research collaboration agreement, estimated period	2 years
Collaboration agreement, revenue recognized	0	700,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments								87,600,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Research Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments								2,500,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Development Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments								36,000,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments								48,300,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Maximum [Member] \| Additional Diagnostic Milestones [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, milestone payments								700,000
Daiichi Sankyo Inc [Member] \| Collaborative Arrangement [Member] \| Upfront Payment Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Collaboration agreement, license revenue								$ 10,100,000